Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Travis T Wager

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of the American Chemical Society|May 5, 2020
Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect SplicingJonathan L Chen, Peiyuan Zhang, Masahito Abe, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 22, 2009
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock periodKevin M Walton, Katherine Fisher, David Rubitski, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2010
Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymesQing-Jun Meng, Elizabeth S Maywood, David A Bechtold, et al.
ACS Chemical Neuroscience|October 8, 2016
Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side EffectsTravis T Wager, Thomas Chappie, David Horton, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189Antonia F Stepan, Tuan P Tran, Christopher J Helal, et al.
Cell Chemical Biology|September 30, 2020
Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoEUthpala Seneviratne, Zhen Huang, Christopher W Am Ende, et al.
Journal of Medicinal Chemistry|September 21, 2011
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)Travis T Wager, Betty A Pettersen, Anne W Schmidt, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of the American Chemical Society|May 5, 2020
Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect SplicingJonathan L Chen, Peiyuan Zhang, Masahito Abe, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 22, 2009
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock periodKevin M Walton, Katherine Fisher, David Rubitski, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2010
Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymesQing-Jun Meng, Elizabeth S Maywood, David A Bechtold, et al.
ACS Chemical Neuroscience|October 8, 2016
Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side EffectsTravis T Wager, Thomas Chappie, David Horton, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189Antonia F Stepan, Tuan P Tran, Christopher J Helal, et al.
Cell Chemical Biology|September 30, 2020
Photoaffinity Labeling and Quantitative Chemical Proteomics Identify LXRβ as the Functional Target of Enhancers of Astrocytic apoEUthpala Seneviratne, Zhen Huang, Christopher W Am Ende, et al.
Journal of Medicinal Chemistry|September 21, 2011
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)Travis T Wager, Betty A Pettersen, Anne W Schmidt, et al.
Pageof 3